Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma-Reference-Cited by-同舟云学术

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

Published:2018-10-29 Issue:12 Volume:24 Page:1877-1886
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Cerezo Michaël^ORCID,Guemiri Ramdane,Druillennec Sabine,Girault Isabelle,Malka-Mahieu Hélène,Shen Shensi^ORCID,Allard Delphine,Martineau Sylvain,Welsch Caroline,Agoussi Sandrine,Estrada Charlène,Adam Julien,Libenciuc Cristina,Routier Emilie,Roy Séverine,Désaubry Laurent,Eggermont Alexander M.,Sonenberg Nahum,Scoazec Jean Yves^ORCID,Eychène Alain^ORCID,Vagner Stéphan^ORCID,Robert Caroline

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-018-0217-1.pdf

Reference58 articles.

1. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

2. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).

3. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).

4. Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

5. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities;Nature Reviews Cancer;2024-09-02

2. DMDA-PatA mediates RNA sequence-selective translation repression by anchoring eIF4A and DDX3 to GNG motifs;Nature Communications;2024-09-02

3. RBM12 drives PD-L1-mediated immune evasion in hepatocellular carcinoma by increasing JAK1 mRNA translation;Oncogene;2024-08-26

4. Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs;Biomedicine & Pharmacotherapy;2024-08

5. PD-L1 at the crossroad between RNA metabolism and immunosuppression;Trends in Molecular Medicine;2024-07